A Study of Eloralintide (LY3841136) in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07701083
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Volunteers

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The main purpose of this study is to learn about safety, tolerability and how well the body processes two different eloralintide solutions. Participation in this study will last about 13 weeks, including screening, inpatient treatment, and follow-up.

Key Dates

First listed
Jul 14, 2026
Start date
Jul 20, 2026
Status verified
Aug 2026
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
58 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Active Comparator: Eloralintide (Reference)
    Participants will receive eloralintide reference formulation administered subcutaneously (SC).
  • Experimental: Eloralintide (Test)
    Participants will receive eloralintide test formulation administered SC.

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide [ Time Frame: Predose on Day 1 through Day 57 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (2)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117
866-429-3700
Hugh Coleman (PRINCIPAL_INVESTIGATOR)
Fortrea Clinical Research UnitDallasTexas75247
866-429-3700
Archie Bowie (PRINCIPAL_INVESTIGATOR)

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TX

Related Studies